$73.24
0.71%
Downside
Day's Volatility :2.78%
Upside
2.09%
3.41%
Downside
52 Weeks Volatility :27.79%
Upside
25.24%
Period | Haemonetics Corp | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -14.45% | 5.1% | 0.0% |
6 Months | -5.8% | 4.9% | 0.0% |
1 Year | -16.69% | 16.6% | 0.0% |
3 Years | 13.57% | 13.2% | -22.3% |
Market Capitalization | 3.8B |
Book Value | $17.7 |
Earnings Per Share (EPS) | 2.19 |
PE Ratio | 33.44 |
PEG Ratio | 1.19 |
Wall Street Target Price | 112.14 |
Profit Margin | 8.61% |
Operating Margin TTM | 19.64% |
Return On Assets TTM | 6.09% |
Return On Equity TTM | 12.98% |
Revenue TTM | 1.3B |
Revenue Per Share TTM | 26.26 |
Quarterly Revenue Growth YOY | 8.0% |
Gross Profit TTM | 530.8M |
EBITDA | 314.1M |
Diluted Eps TTM | 2.19 |
Quarterly Earnings Growth YOY | -0.07 |
EPS Estimate Current Year | 3.96 |
EPS Estimate Next Year | 4.4 |
EPS Estimate Current Quarter | 1.0 |
EPS Estimate Next Quarter | 1.09 |
What analysts predicted
Upside of 53.11%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 967.6M | ↑ 7.04% |
Net Income | 55.0M | ↑ 20.73% |
Net Profit Margin | 5.69% | ↑ 0.65% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 988.5M | ↑ 2.16% |
Net Income | 76.5M | ↑ 39.09% |
Net Profit Margin | 7.74% | ↑ 2.05% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 870.5M | ↓ 11.94% |
Net Income | 79.5M | ↑ 3.85% |
Net Profit Margin | 9.13% | ↑ 1.39% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 993.2M | ↑ 14.1% |
Net Income | 43.4M | ↓ 45.42% |
Net Profit Margin | 4.37% | ↓ 4.76% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 1.2B | ↑ 17.67% |
Net Income | 115.4M | ↑ 166.05% |
Net Profit Margin | 9.87% | ↑ 5.5% |
FY24 | Y/Y Change | |
---|---|---|
Revenue | 1.3B | ↑ 12.01% |
Net Income | 117.6M | ↑ 1.87% |
Net Profit Margin | 8.98% | ↓ 0.89% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 304.4M | ↓ 0.29% |
Net Income | 29.4M | ↓ 10.81% |
Net Profit Margin | 9.65% | ↓ 1.14% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 311.3M | ↑ 2.27% |
Net Income | 41.0M | ↑ 39.68% |
Net Profit Margin | 13.18% | ↑ 3.53% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 318.2M | ↑ 2.2% |
Net Income | 24.9M | ↓ 39.31% |
Net Profit Margin | 7.83% | ↓ 5.35% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 336.3M | ↑ 5.68% |
Net Income | 31.2M | ↑ 25.43% |
Net Profit Margin | 9.29% | ↑ 1.46% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 343.3M | ↑ 2.09% |
Net Income | 20.4M | ↓ 34.81% |
Net Profit Margin | 5.93% | ↓ 3.36% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 336.2M | ↓ 2.07% |
Net Income | 38.4M | ↑ 88.41% |
Net Profit Margin | 11.41% | ↑ 5.48% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.3B | ↑ 3.02% |
Total Liabilities | 606.9M | ↑ 25.16% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.3B | ↓ 0.6% |
Total Liabilities | 680.0M | ↑ 12.05% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.8B | ↑ 43.63% |
Total Liabilities | 1.1B | ↑ 60.04% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.9B | ↑ 2.19% |
Total Liabilities | 1.1B | ↑ 2.03% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 1.9B | ↑ 4.04% |
Total Liabilities | 1.1B | ↑ 0.59% |
FY24 | Y/Y Change | |
---|---|---|
Total Assets | 2.2B | ↑ 13.48% |
Total Liabilities | 1.2B | ↑ 10.64% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.9B | ↑ 3.02% |
Total Liabilities | 1.1B | ↑ 1.34% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.0B | ↑ 1.42% |
Total Liabilities | 1.1B | ↓ 1.72% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.0B | ↑ 2.5% |
Total Liabilities | 1.1B | ↑ 1.82% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.2B | ↑ 9.4% |
Total Liabilities | 1.3B | ↑ 12.48% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 2.2B | ↓ 0.22% |
Total Liabilities | 1.2B | ↓ 1.71% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 2.5B | ↑ 15.73% |
Total Liabilities | 1.6B | ↑ 32.37% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 159.3M | ↓ 27.71% |
Investing Cash Flow | -116.1M | ↑ 84.24% |
Financing Cash Flow | -50.6M | ↓ 58.03% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 158.2M | ↓ 0.67% |
Investing Cash Flow | -57.2M | ↓ 50.77% |
Financing Cash Flow | -131.2M | ↑ 159.16% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 108.8M | ↓ 31.23% |
Investing Cash Flow | -425.4M | ↑ 644.09% |
Financing Cash Flow | 367.5M | ↓ 380.05% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 172.3M | ↑ 58.32% |
Investing Cash Flow | -86.3M | ↓ 79.7% |
Financing Cash Flow | -15.7M | ↓ 104.29% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 273.1M | ↑ 58.51% |
Investing Cash Flow | -143.8M | ↑ 66.53% |
Financing Cash Flow | -100.4M | ↑ 537.27% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 79.6M | ↑ 23.59% |
Investing Cash Flow | -18.0M | ↓ 50.67% |
Financing Cash Flow | -1.6M | ↓ 96.77% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 19.1M | ↓ 76.03% |
Investing Cash Flow | -15.3M | ↓ 15.24% |
Financing Cash Flow | -598.0K | ↓ 62.69% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 99.1M | ↑ 419.35% |
Investing Cash Flow | -25.1M | ↑ 64.7% |
Financing Cash Flow | -7.2M | ↑ 1099.33% |
Sell
Neutral
Buy
Haemonetics Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Haemonetics Corp | -14.56% | -5.8% | -16.69% | 13.57% | -39.51% |
![]() Intuitive Surgical, Inc. | 5.02% | 20.15% | 58.74% | 31.28% | 184.98% |
![]() Resmed Inc. | 16.09% | 27.14% | 62.7% | -17.28% | 81.24% |
![]() Becton, Dickinson And Company | 0.02% | -2.08% | -12.88% | -9.76% | -9.75% |
![]() West Pharmaceutical Services Inc | 1.18% | -17.93% | -26.4% | -35.64% | 104.36% |
![]() Alcon Ag | 3.83% | 8.9% | 15.02% | 11.44% | 61.54% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Haemonetics Corp | 33.44 | 33.44 | 1.19 | 3.96 | 0.13 | 0.06 | NA | 17.7 |
![]() Intuitive Surgical, Inc. | 81.91 | 81.91 | 4.06 | 6.65 | 0.16 | 0.08 | NA | 41.4 |
![]() Resmed Inc. | 35.33 | 35.33 | 2.05 | 7.71 | 0.23 | 0.13 | 0.01 | 33.11 |
![]() Becton, Dickinson And Company | 46.72 | 46.72 | 1.08 | 13.11 | 0.06 | 0.03 | 0.02 | 89.5 |
![]() West Pharmaceutical Services Inc | 42.71 | 42.71 | 5.15 | 6.51 | 0.2 | 0.11 | 0.0 | 35.49 |
![]() Alcon Ag | 42.64 | 42.64 | 3.53 | 3.05 | 0.05 | 0.03 | 0.0 | 42.35 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Haemonetics Corp | Buy | $3.8B | -39.51% | 33.44 | 8.61% |
![]() Intuitive Surgical, Inc. | Buy | $169.4B | 184.98% | 81.91 | 27.65% |
![]() Resmed Inc. | Buy | $36.0B | 81.24% | 35.33 | 21.79% |
![]() Becton, Dickinson And Company | Buy | $67.4B | -9.75% | 46.72 | 7.13% |
![]() West Pharmaceutical Services Inc | Buy | $21.8B | 104.36% | 42.71 | 18.25% |
![]() Alcon Ag | Buy | $46.7B | 61.54% | 42.64 | 11.44% |
Insights on Haemonetics Corp
Revenue is down for the last 2 quarters, 343.29M → 336.17M (in $), with an average decrease of 2.1% per quarter
Netprofit is up for the last 2 quarters, 20.36M → 38.37M (in $), with an average increase of 46.9% per quarter
In the last 1 year, Resmed Inc. has given 62.7% return, outperforming this stock by 79.4%
Capital Research Global Investors
BlackRock Inc
Vanguard Group Inc
Wellington Management Company LLP
Neuberger Berman Group LLC
State Street Corporation
haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right
Organization | Haemonetics Corp |
Employees | 3657 |
CEO | Mr. Christopher A. Simon |
Industry | Health Technology |
Assetmark Financial Holdings Inc
$73.24
-1.8%
Fidelity Msci Health Care Etf
$73.24
-1.8%
Texas Capital Bancshares Inc.
$73.24
-1.8%
Primerica, Inc.
$73.24
-1.8%
Thor Industries Inc.
$73.24
-1.8%
Qifu Technology Inc
$73.24
-1.8%
Crinetics Pharmaceuticals Inc
$73.24
-1.8%
Hercules Capital Inc
$73.24
-1.8%
Janus Henderson Mortgage-backed Securities Etf
$73.24
-1.8%